Disclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.
|
|
- Corey Welch
- 8 years ago
- Views:
Transcription
1 Disclosure I have no actual or potential conflict of interest in relation to this presentation. Sarah Lombardo, MD., MSc. General Surgery, University of Utah September 9, 2015 Objectives Outline Recognize common oral anticoagulants (OATs) Understand mechanisms of common OATs Understand indications and dosing of reversal agents for common OATs Understand the risks associated with reversal Understand applicability of reversal agents in the trauma patient Mechanisms of traditional and novel OATs Reversal strategies R-I-S-K, find out what it means to me Reversal in the hemodynamically unstable trauma patient Reversal in the TBI patient
2 Coagulation Cascade 1. Vitamin K inhibitor The Cascade 2. Direct Xa inhibitor 3. Direct thrombin inhibitor The Usual Suspects Review of Oral Anticoagulants Warfarin Rivaroxaban Apixaban Edoxaban Clopidogrel
3 Warfarin (aka: Coumadin) Rivaroxaban (aka: Xarelto) Mechanism: vitamin K antagonist Indications: 1) atrial fibrillation 2) VTE prophylaxis 3) VTE treatment Half-life: hours (effective) Dosing: Titrated to goal INR 2-3, or 2.5 to 3.5 Tests: INR/PT Mechanism: direct Factor Xa inhibitor Indications: 1) atrial fibrillation 2) VTE prophylaxis Half-life: 5-9 hours (11-13 hour > 65 yo) Dosing: 10 to 20mg, q12 to q24h Tests: anti-factor Xa activity, PT, TEG Apixaban Dabigatran (aka: Pradaxa) Mechanism: direct Factor Xa inhibitor Mechanism: direct thrombin inhibitor Indications: 1) atrial fibrillation 2) VTE prophylaxis 3) VTE treatment Indications: 1) atrial fibrillation 2) VTE prophylaxis 3) VTE treatment Half-life: 8-15 hours Dosing: 2.5 to 5mg, q12 to q24h Tests: PT, PTT, INR, anti-factor Xa activity, TEG Half-life: hours Dosing: 150mg bid Tests: ecarin clot time (ECT), PTT, thrombin time, TEG
4 Clopidogrel (aka: Plavix) Mechanism: irreversibly blocks ADP release Indications: 1) CAD, including ACS, stent Half-life: 6 hours 2) PAD 3) Stroke prevention Dosing: 75mg daily Tests: platelet function testing, TEG Thrombin time Reversal Strategies Reversal Strategies Antidote Vitamin K Idarucizumab? Factor Replacement FFP PCC Factor VIIa
5 Factor Replacement FFP (aka: plasma) Fresh Frozen Plasma (FFP) Prothrombin Complex Concentrate (PCC) Activated Prothrombin Complex Concentrate (apcc) Activated Factor VII (FVIIa) Indications: Hemorrhage associated with warfarin use, deficiency of multiple coagulation factors, and massive transfusion Brand N/A Kcentra FEIBA NovoSeven Factors +/- II, V, VII, IX, X, XI, vwf, fibrinogen High volume Leukocytes Thaw time II, VII, IX, X II, VIIa, IX, X rviia Low volume Thrombosis Low volume Thrombosis Low volume Cost Efficacy Dosing: time. Target factors at >30% normal. Often requires ~15 ml/kg of FFP. 30 min thaw time. 30 min transfusion PCC (aka: Kcentra) apcc (aka: FEIBA) Indications: Dosing: Urgent reversal of Vitamin K antagonist in patients with major bleed or for urgent procedure INR 2 to < 4: 25 units/kg (max 2500 units) INR 4 to 6: 35 units/kg (max 3500 units) INR >6: 50 units/kg (max 5000 units) Administer with Vitamin K. Repeat dosing not recommended. Indications: Dosing: Hemorrhage, peri-procedural, or prophylaxis for bleeding events in patients with hemophilia units/kg, may repeat Correction of INR to < 1.5 with single dose within approximately 30 minutes
6 rfviia (aka: NovoSeven) Warfarin (aka: Coumadin) Indications: Dosing: Hemorrhage and perioperative management of hemophiliacs, congenital FVII deficiency, and Glanzmann s thrombocytopenia 10 to 100 mcg/kg Administer with IV Vitamin K. May need to repeat dosing based on INR. Mechanism: Vit K antagonist Reversal agents: vitamin K Dialyzable: No Factors: FFP, PCC Warfarin (aka: Coumadin) Non-bleeding patient Warfarin (aka: Coumadin) Bleeding patient INR < 5 INR 5-9 INR >9 Minimal INR > 5 Urgent or procedural Life threatening Hold next dose Hold next dose Oral Vit K (1-2.5mg) Hold next dose Oral Vit K (2.5-5mg) Hold next dose Vitamin K (IV or PO) Hold next dose Vitamin K (10mg IV) PCC (4- factor) PCC DDAVP FFP/Plts/R BC Hold next dose Vitamin K (10mg IV) Tranexamic acid
7 Rivaroxaban (aka: Xarelto) Rivaroxaban (aka: Xarelto) Mechanism: FXa inhibitor Reversal agent: None Dialyzable: No Factors: PCC, apcc, rfviia Phase 1 12 subjects Cross-over study Eerenberg et. al., Circulation 2011 Rivaroxaban (aka: Xarelto) Apixaban Mechanism: FXa inhibitor Reversal agent: None Dialyzable: No Factor: PCC, apcc, rfviia Eerenberg et. al., Circulation 2011
8 Apixaban Apixaban In vitro 10 healthy subjects Apixaban added to blood samples MacDonald and Luddington, Semin Thromb Hemost Apixaban Apixaban Escolar et. al., PLoS One Escolar et. al., PLoS One. 2013
9 Apixaban Dabigatran (aka: Pradaxa) Mechanism: thrombin inhibitor Reversal agent: idarucizumab Dialyzable: Yes (>50%, 4 hours) Factor : apcc, rfviia Escolar et. al., PLoS One Rivaroxaban (aka: Xarelto) Rivaroxaban (aka: Xarelto) Phase 1 12 subjects Cross-over study Eerenberg et. al., Circulation 2011 Eerenberg et. al., Circulation 2011
10 Dabigatran (aka: Pradaxa) Monoclonal antibody to dabigatran Prospective cohort Eerenberg et. al., Circulation subjects Group A (n=51) = life-threatening bleed Group B (n=39) = required procedure Thrombin time Ecarin clot time
11 Clopidogrel (aka: Plavix) Reversal Summary 4- Factor PCC Activated PCC Activated Factor VII Antidote Mechanism: irreversible platelet aggregation inhibitor Reversal agent: None Dialyzable: No Factor: platelets, desmopressin (DDAVP) Brand name Kcentra FEIBA NovoSeven N/A Factors II, VII, IX, X II, VIIa, IX, X VIIa N/A Coagulopathy Reversal Warfarin Yes Yes Yes Vitamin K Rivaroxaban Maybe Yes Maybe None Apixaban Maybe Yes Maybe None Dabigatran No Maybe Maybe Idarucizumab OATs and Trauma Outcomes Bleeding rates on novel OATs vs. warfarin are comparable Spontaneous vs. trauma-associated R-I-S-K OAT use associated with worse outcomes Warfarin vs. antiplatelet agents Elderly TBI Early reversal may reduce hemorrhage progression
12 Risks of Rapid Reversal FFP PCC, apcc rfviia Fluid overload Viral transmission Thromboembolic events Arterial thrombosis Clinical Case Allergic reaction Clinical Case: Ruth Clinical Case: Imaging 80 yo F Transfer: new onset stoke-like symptoms PMHx: polio, HTN, valve replacement Meds: ASA 81mg, coumadin Physical exam Old bruising over left eyebrow No neural deficits Intermittent slurring of words Waxing waning exam Labs INR 2.3 Plts 198 Hgb 13.1 Imaging.
13 Clinical Case: Management Traumatic Brain Injury Questions Actively bleeding? Symptomatic? Next steps Hold anticoagulants Vitamin K Repeat CT head Consult to Neurosurgery Reversal not shown to improve outcomes, but may reduce progression EAST guidelines Begin therapy to correct INR within 2 hours INR at < 1.6 by 4 hours Do not reverse patients with head injury who lack radiologic findings Platelet transfusion not shown to reduce mortality or alter outcomes Concerns with prior study designs Recommendations: 5-10 U platelets, desmopressin References Baumann-Kreuziger LM, Morton CT, Dries DJ. New anticoagulants: a concise review. J Trauma Acute Care Surg, 2012;73(4): Erenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healhty subjects. Circulation, 2011;124: Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alteraions in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS ONE, 2013;8(11):e Freeman WD, Aguilar MI, Weitz J.. Reversal of anticoagulation in warfarin-associated intracranial hemorrhage. In: UpToDate, Leung LLK, Kasner SE (Eds), UpToDate, Waltham, MA. (Accessed on September 5, 2015.). Grandhi R, Harrison G, Voronovich Z, et al. Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients. J Trauma Acute Care Surg, 2014;78(3): Hull RD, Garcia DA. Management of warfarin-associated bleeding or supratherapeutic INR. In: UpToDate, Leung LLK (Ed), UpToDate, Waltham, MA. (Accessed on September 5, 2015.). MacDonald SG, Luddington RJ. Critical factors contributing to the thromboelastography trace. Semin Thromb Hemost, 2010;36(7): McCoy CC, Lawson JH, Shapiro ML. Management of anticoagulation agents in trauma patients. Clin Lab Med, 2014;34(3): Moorman ML, Nash JE, Stabi KL. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban. J Trauma Acute Care Surg, 2014;77(3): Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med, 2015;373: Schochl H, Voelckel W, Maegele M, et al. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients. Critical Care, 2014;18:R147.
Critical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationTo assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).
MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationMANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
More informationOral anticoagulants new and old: bleeding risk and management strategies. Logan Tinsen Pharm.D. Benefis Hospitals
Oral anticoagulants new and old: bleeding risk and management strategies Logan Tinsen Pharm.D. Benefis Hospitals Disclaimer! I am not receiving any compensation from any drug company! Any opinions I may
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationDisclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationThe management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationDisclosures. Objective (NRHS) Self Assessment #2
Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationCONTEMPORARY REVERSAL OF ANTICOAGULATION
CONTEMPORARY REVERSAL OF ANTICOAGULATION Michael S. McHale, M.D., F.A.C.P. Avera Medical Group Hematology & Oncology Medications Coumadin / Warfarin Unfractionated Heparin Low Molecular Weight Heparin
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationQUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
More informationNON-VITAMIN K ORAL ANTICOAGULANT REVERSAL
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationNON-VITAMIN K ORAL ANTICOAGULANT REVERSAL
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationHigh Risk Emergency Medicine
High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose
More informationRecommendation for the Reversal of Novel Anticoagulants in Emergent Situations
Lauren Edwards PharmD Candidate 2016 Truman Medical Center, Lakewood Preceptor: Dr. Melissa Gabriel June 11, 2015 Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations Background
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationNow We Got Bad Blood: New Anticoagulant Reversal
Now We Got Bad Blood: New Anticoagulant Reversal Kellie Rodriguez, PharmD, BCPS PGY2 Emergency Medicine Pharmacy Resident UF Health Jacksonville January 2016 Objectives 1. Review current treatment strategies
More informationPulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
More informationNew Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More information10/16/2013. Reversal of Anticoagulants: Something New Under the Sun? Disclosures. Pharmacist Objectives
Reversal of Anticoagulants: Something New Under the Sun? Zachariah Thomas, PharmD, BCPS Clinical Associate Professor Ernest Mario School of Pharmacy Rutgers, the State University of New Jersey Clinical
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationOral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationHow does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized?
Anticoagulation reversal Vitamin K antagonists and New Oral Anticoagulants Robert Orman, MD Warfarin How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More information3/17/2014. No conflicts of interest to report
No conflicts of interest to report Patrick M. Lewis, Pharm.D., BCPS, CACP Lahey Hospital & Medical Center Burlington, MA April 1 st 2014 Parts of this presentation discuss off-label use of reversal agents.
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationNo more rat poison? New oral anticoagulants and perioperative considerations
1 No more rat poison? New oral anticoagulants and perioperative considerations Jerrold H. Levy, MD, FAHA, FCCM Professor Department of Anesthesiology/Critical Care Duke University School of Medicine Durham,
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationManaging Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN
Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting Amy Huggins, BSN, RN Objectives 1 2 3 4 5 Recognize bleeding risk based on classes of IR procedures Differentiate
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationReversal of Old and New Antithrombotic Drugs. Mike Makris
Reversal of Old and New Antithrombotic Drugs Mike Makris BCSH guidelines Guidelines on oral anticoagulation with warfarin fourth edition 1 Guideline on the urgent or emergency reversal of antithrombotic
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationAnticoagulant Reversal
No Conflicts of Interest to Report Anticoagulant Reversal Matthew Bondi Pharm.D., BCPS March 14, 2015 Matthew Bondi Pharm.D., BCPS. Clinical Pharmacist Sparrow Hospital Matthew.bondi@sparrow.org Ph. 517.364.2031
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationReversing novel anticoagulants to divert catastrophe SEAN P. WILSON, MD DEPARTMENT OF EMERGENCY MEDICINE HENRY FORD HOSPITAL, DETROIT, MI
Reversing novel anticoagulants to divert catastrophe SEAN P. WILSON, MD DEPARTMENT OF EMERGENCY MEDICINE HENRY FORD HOSPITAL, DETROIT, MI Novel anticoagulants? Dabigatran (Pradaxa) Stroke and systemic
More informationRecommendations on Use of Dabigatran in Atrial Fibrillation
Recommendations on Use of Dabigatran in Atrial Fibrillation Developed by participants from the Section of Hematology/Oncology and Section of Cardiology, and Faculty of Pharmacy, University of Manitoba
More informationCHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS. Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital
CHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital 1 2 Disclosure I do not have a vested interest in or affiliation
More informationTop 10 Thrombosis and Anticoagulation Highlights from ASH 2014
Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014 Stephan Moll, MD UNC School of Medicine, Chapel Hill, NC 1. New Anticoagulant Factor XI lowering drug NEJM publication Dec 7 th (late- breaking
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationEmergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies
AACN Advanced Critical Care Volume 25, Number 1, pp. 5-12 2014 AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Emergent Reversal of Oral Anticoagulation:
More informationManagement of New Oral Anticoagulant Agents in Alberta Health Services
Mom New Oral Anticoagulant (NOAC) Agent Guideline Working Group Testing Supportive Therapy Drug Dosing Management of New Oral Anticoagulant Agents in Alberta Health Services There are three new oral anticoagulant
More informationOAC and NOAC with or without platelet inhibition
Zürich 11.06.2015 Preoperative antithrombotic management OAC and NOAC with or without platelet inhibition Miodrag Filipovic miodrag.filipovic@kssg.ch Anästhesiologie & Intensivmedizin Case 1 76 yr old
More informationNew Oral Anticoagulants (NOACs)
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Janice Lawson, MD Tallahassee Memorial Hospital Cancer and Hematology Specialists Disclosure
More informationReview of Newer Antiplatelets, Antithrombotics and Reversal
Review of Newer Antiplatelets, Antithrombotics and Reversal Ravi Sarode, MD Professor of Pathology Chief of Pathology and Medical Director of Clinical Laboratory Services Director, Transfusion Medicine
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationAdult Inpatient/Emergency Department Procoagulant Clinical Practice Guideline (CPG) Cover Sheet
Adult Inpatient/Emergency Department Procoagulant Clinical Practice Guideline (CPG) Cover Sheet Target Population: Adult inpatients and emergency department patients with sustained bleeding requiring administration
More informationDisclosures. Overview. Anticoagulation in 2015: Where We Are and Where We Are Going. Impact of NOACs in Canada
Anticoagulation in 2015: Where We Are and Where We Are Going Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More informationProgram Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationNovel Anticoagulants
Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota
More informationNovel oral anticoagulants (NOACs): novel problems and their solutions
Novel oral anticoagulants (NOACs): novel problems and their solutions Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center January 2013 OVERVIEW NOACs in clinical use Review of pivotal
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationEmerging therapies for Intracerebral Hemorrhage
Emerging therapies for Intracerebral Hemorrhage Chitra Venkat, MBBS, MD, MSc. Associate Professor of Neurology and Neurological Sciences Stroke and Neurocritical Care. Stanford University Learning objectives
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More information